Chart-Typ:
Zeitraum:
| Riot Platforms, Inc.: Riot Platforms Reports Full Year 2025 Financial Results and Strategic Highlights | Record annual revenue of $647.4 million with 5,686 bitcoin minedImproved positioning of Corsicana and Rockdale sites through strategic land acquisitionsData center lease with AMD operational CASTLE... ► Artikel lesen |
| Aktien New York Ausblick: Dow etwas leichter zum Wochenauftakt | NEW YORK (dpa-AFX) - An den US-Börsen zeichnen sich zum Wochenauftakt moderate Verluste ab. Die Preise für Gold und Silber erholten sich am Montag nach anfänglichen erneuten hohen Verlusten, damit... ► Artikel lesen |
| Riot Platforms, Inc.: Riot Announces December 2025 Production and Operations Updates | CASTLE ROCK, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) ("Riot" or "the Company"), a Bitcoin-driven industry leader in the development of large-scale data centers... ► Artikel lesen |
| Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26
Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity... ► Artikel lesen |
| Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen |
| Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity | Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens
Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen |
| Astria Therapeutics, Inc.: Stockholders Vote to Approve Acquisition by BioCryst Pharmaceuticals, Inc. | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAMSONITE INTERNATIONAL SA ADR finden Sie auf Wallstreet Online.